Shelby Newsad

Shelby Newsad is a Partner at Compound based in New York City, where she specializes in biotechnology and healthcare venture capital investments. Since joining the thesis-driven firm in July 2022, she has focused on Seed and Series A funding rounds, deploying initial capital ranging from $100,000 to $3 million per transaction. Prior to entering the institutional venture capital industry, she conducted extensive scientific research across multiple disciplines, including neuroscience at the National Institutes of Health and drug discovery at the Helmholtz Institute. She also earned a doctorate in plant sciences from the University of Cambridge, providing a deep technical foundation for her early-stage investment strategy. Currently managing a portfolio of over twenty active investment theses, Newsad leverages her academic and clinical research background to identify step-change technological advancements across the broader global life sciences sector.